US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NervGen Pharma Corp.

4.08

-0.0799-1.92%

Volume:30.30K

Turnover:126.94K

Market Cap:330.21M

PE:-9.17

High:4.25

Open:4.20

Low:4.08

Close:4.16

52wk High:6.30

52wk Low:1.50

Shares:80.93M

Float Shares:66.17M

Volume Ratio:0.54

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.4448

EPS(LYR):-0.4448

ROE:-1457.57%

ROA:-73.42%

PB:129.79

PE(LYR):-9.17

Loading ...

Overview Company News Filings

NervGen Pharma to present at Bloom Burton Healthcare Investor Conference

NervGen Pharma price target raised to $12 from $10 at Maxim

BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury

NervGen wins FDA alignment for Phase 3 NVG-291 trial in chronic tetraplegia

NervGen Pharma Corp - to Conclude Enrollment in Phase 1B/2a Connect Sci Subacute Tetraplegia and Unblind Data

THOMSON REUTERS

NervGen Pharma Corp - Restore Study Initiation on-Track for Mid-2026

THOMSON REUTERS

NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on Restore, a Phase 3 Registrational Study of Nvg-291 for Chronic Tetraplegia

THOMSON REUTERS

NervGen FY25 net loss widens to $44.1 million; cash and investments climb to $22 million

BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business Updates

Press Release: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

NervGen Pharma to Delist From TSX Venture Exchange

MT Newswires Live

NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs

NervGen Pharma to Participate at Upcoming Investor Conferences

NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams

NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium

NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NGEN/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NGEN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","market":"US","secType":"STK","nameCN":"NervGen Pharma Corp.","latestPrice":4.0801,"timestamp":1776438492513,"preClose":4.16,"halted":0,"volume":30295,"delay":0,"changeRate":-0.01920673076923084,"floatShares":66170854,"shares":80930900,"eps":-0.444846,"marketStatus":"Trading","change":-0.0799,"latestTime":"04-17 11:08:37 EDT","open":4.2,"high":4.25,"low":4.0801,"amount":126937.352685,"amplitude":0.040841,"askPrice":4.19,"askSize":3000,"bidPrice":4.06,"bidSize":2500,"shortable":3,"etf":0,"ttmEps":-0.444846,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776456000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.16,"preHourTrading":{"tag":"盘前","latestPrice":4.28,"preClose":4.16,"latestTime":"07:59 EDT","volume":378,"amount":1621.514916,"timestamp":1776427162560,"change":0.12,"changeRate":0.028846,"amplitude":0.021635},"postHourTrading":{"tag":"盘后","latestPrice":4.08,"preClose":4.16,"latestTime":"19:22 EDT","volume":148,"amount":606.1816,"timestamp":1776381747902,"change":-0.08,"changeRate":-0.019231,"amplitude":0.019231},"volumeRatio":0.536769,"impliedVol":3.6503,"impliedVolPercentile":0.8833},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NGEN\",,,,,undefined,":{"symbol":"NGEN","floatShares":66170854,"roa":"-73.42%","roe":"-1457.57%","lyrEps":-0.444846,"volumeRatio":0.536769,"shares":80930900,"dividePrice":0,"high":4.25,"amplitude":0.040841,"preClose":4.16,"low":4.0801,"week52Low":1.5,"pbRate":"129.79","week52High":6.3,"institutionHeld":0,"latestPrice":4.0801,"committee":-0.090909,"eps":-0.444846,"divideRate":0,"volume":30295,"delay":0,"ttmEps":-0.444846,"open":4.2,"prevYearClose":5.6,"prevWeekClose":4.05,"prevMonthClose":3.77,"prevQuarterClose":3.77,"fiveDayClose":4.05,"twentyDayClose":3.97,"sixtyDayClose":5.21},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NGEN\",params:#limit:5,,,undefined,":[{"date":"2026-03-31","symbol":"NGEN","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774944000000,"name":null,"time":"Pre-Market","dateTimestamp":1774929600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NGEN\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NGEN\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":4,"updateTime":1775793600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NGEN\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NGEN","date":"2026-04-16","current":-9.295352,"percent":0.924242,"low":-25.148356,"twenty":-19.352187,"median":-17.285978,"eighty":-16.234567,"high":-10.084942,"avg":-17.477831,"sd":3.663084,"marketCap":343146893},"quantilePoints":[{"date":"2026-01-09","current":-25.148356,"twenty":-24.98651,"median":-24.743741,"eighty":-24.500973,"marketCap":463798962.95},{"date":"2026-01-16","current":-23.484013,"twenty":-24.651705,"median":-24.262661,"eighty":-23.546305,"marketCap":432253265.53},{"date":"2026-01-23","current":-22.238177,"twenty":-24.339127,"median":-23.484013,"eighty":-22.456198,"marketCap":412101315.23},{"date":"2026-01-30","current":-17.441707,"twenty":-24.262661,"median":-22.611928,"eighty":-20.307131,"marketCap":329508465.32},{"date":"2026-02-06","current":-16.382746,"twenty":-23.795472,"median":-22.238177,"eighty":-17.908896,"marketCap":306238051.42},{"date":"2026-02-13","current":-17.441707,"twenty":-23.484013,"median":-19.886661,"eighty":-17.285978,"marketCap":327197651.85},{"date":"2026-02-20","current":-18.220355,"twenty":-23.359429,"median":-18.282647,"eighty":-17.285978,"marketCap":340388899.6},{"date":"2026-02-27","current":-17.753166,"twenty":-22.879782,"median":-18.03348,"eighty":-17.410561,"marketCap":331850071.27},{"date":"2026-03-06","current":-17.223686,"twenty":-22.51849,"median":-17.893323,"eighty":-17.27352,"marketCap":321208516.98},{"date":"2026-03-13","current":-16.382746,"twenty":-22.306698,"median":-17.753166,"eighty":-16.993207,"marketCap":307553178.63},{"date":"2026-03-20","current":-16.957011,"twenty":-22.250635,"median":-17.753166,"eighty":-16.888553,"marketCap":316207550},{"date":"2026-03-27","current":-15.785094,"twenty":-21.714925,"median":-17.597437,"eighty":-16.837477,"marketCap":291516280},{"date":"2026-04-02","current":-18.89617,"twenty":-20.942507,"median":-17.535145,"eighty":-16.702393,"marketCap":347270760},{"date":"2026-04-10","current":-10.676925,"twenty":-19.970755,"median":-17.441707,"eighty":-16.494872,"marketCap":340718966},{"date":"2026-04-16","current":-10.665661,"twenty":-19.352187,"median":-17.285978,"eighty":-16.234567,"marketCap":343146893}],"updateTime":1776438516203},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NGEN\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627303954","title":"NervGen Pharma to present at Bloom Burton Healthcare Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2627303954","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627303954?lang=en_us&edition=fundamental","pubTime":"2026-04-13 19:45","pubTimestamp":1776080739,"startTime":"0","endTime":"0","summary":"NervGen executives scheduled to join H.C. Wainwright HCW@Home virtual fireside chat April 15, 2026.Bloom Burton Healthcare Investor Conference presentation set for April 22, 2026 in Toronto.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL5Qzzxk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","IE00BN0W2V16.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","BK4588","LU2210150020.SGD","BK4585","LU2210149790.SGD","SG9999014039.USD","BK4007","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626392458","title":"NervGen Pharma price target raised to $12 from $10 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2626392458","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626392458?lang=en_us&edition=fundamental","pubTime":"2026-04-09 03:20","pubTimestamp":1775676016,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on NervGen Pharma (NGEN) to $12 from $10 and keeps a Buy rating on the shares, citing alignment with the FDA o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-raised-to-12-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nervgen-pharma-price-target-raised-to-12-from-10-at-maxim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NGEN","LABU","BK4588","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625195846","title":"BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2625195846","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625195846?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:36","pubTimestamp":1775565370,"startTime":"0","endTime":"0","summary":"BUZZ-NervGen rises after FDA backs late-stage study to test drug for spinal cord injury** Shares of biotech firm NervGen Pharma NGEN.O rise 7% to $4.71 premarket** Co says the FDA agreed on the design of a late-stage study for its experimental drug for spinal cord injury, NVG-291,  that aims to improve hand movement in people with chronic paralysis of all four limbs** Co says the 16-week study in about 150 adults in the U.S. and Canada will test whether daily injections improve fine hand use versus placebo ** Says the FDA alignment follows earlier results showing better hand function, bladder control and less muscle stiffness in treated patients** Adds the trial is expected to start in mid-2026; NVG-291 already has FDA fast-track status** As of last close, stock down ~22% YTD  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nL4N40Q0UQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937930","title":"NervGen wins FDA alignment for Phase 3 NVG-291 trial in chronic tetraplegia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937930","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937930?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:38","pubTimestamp":1775561918,"startTime":"0","endTime":"0","summary":"NervGen reported FDA alignment on RESTORE, a Phase 3 registrational trial of NVG-291 in adults with chronic tetraplegia, with study start targeted for mid-2026.Phase 1b/2a CONNECT SCI results were already presented as support for Phase 3, showing NVG-291 improved hand function versus placebo and benefits persisted beyond dosing.Patient-reported outcomes in CONNECT SCI indicated more participants on NVG-291 felt meaningfully improved, supporting potential real-world impact on daily independence.RESTORE will enroll about 150 subjects across up to 60 sites in US and Canada, with an optional open-label extension designed to broaden access for placebo recipients.NervGen elected to stop enrollment in subacute tetraplegia cohort of CONNECT SCI and unblind available data to apply Phase 3 endpoint framework to a future study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL5BMp5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625937302","title":"NervGen Pharma Corp - to Conclude Enrollment in Phase 1B/2a Connect Sci Subacute Tetraplegia and Unblind Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2625937302","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625937302?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NGEN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625373729","title":"NervGen Pharma Corp - Restore Study Initiation on-Track for Mid-2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2625373729","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625373729?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625373089","title":"NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on Restore, a Phase 3 Registrational Study of Nvg-291 for Chronic Tetraplegia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625373089","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625373089?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:30","pubTimestamp":1775561400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nTUA4DFBKY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624555644","title":"NervGen FY25 net loss widens to $44.1 million; cash and investments climb to $22 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624555644","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624555644?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:36","pubTimestamp":1774993004,"startTime":"0","endTime":"0","summary":"NervGen posted a net loss of $44.1 million, or $0.61 per share.Non-cash items totaled $24.8 million within the annual loss.R&D expense fell to $13.9 million due to completion of chronic CONNECT SCI cohort and lower preclinical spending.G&A costs climbed to $11.2 million on higher legal and professional fees tied to Nasdaq listing.Cash and investments rose to $22.1 million; Phase 3 in chronic tetraplegia remains on track for mid-2026 with FDA regulatory update expected in early 2Q 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL39P81j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","NDAQ","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BN0W2V16.EUR","SG9999014013.SGD","LU2210149790.SGD","BK4588","LU2210150020.SGD","SG9999014039.USD","NGEN","IE00B64PRP62.GBP","BK4007","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623821525","title":"BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623821525","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623821525?lang=en_us&edition=fundamental","pubTime":"2026-03-31 21:29","pubTimestamp":1774963776,"startTime":"0","endTime":"0","summary":"BRIEF-Nervgen Pharma Reports Full Year 2025 Financial Results And Provides Business UpdatesNervGen Pharma Corp NGEN.O:NERVGEN PHARMA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATESSource text: ID:nGNX6jn2DNFurther company coverage: NGEN.O","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nTUA1CKGSD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623863765","title":"Press Release: NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2623863765","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623863765?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:46","pubTimestamp":1774957560,"startTime":"0","endTime":"0","summary":"-- Completed End-of-Phase 2 meeting with the FDA; Company expects to provide. a regulatory update in early 2Q 2026 and remains on track to initiate a. Phase 3 study in chronic tetraplegia in mid-2026.-- Company expects to present clinical data from independent, blinded. providing additional evidence with the potential to further support the. systemic biological effect of NVG-291, differentiating genuine neural. -- Company expects to expand NVG-291 into complementary clinical indications,as informed by established preclinical efficacy, with prioritization. supports the Company's emergence as a leader in the development of. \"2025 was a transformative year for NervGen, but more importantly the SCI community,\" said Adam Rogers, MD, President and Chief Executive Officer of NervGen. \"We've demonstrated the potential best-in-class profile of NVG-291 and its ability to meaningfully improve the lives of those with chronic tetraplegia in the CONNECT SCI study, and we continue to strengthen our u","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","SCI","LU0077335932.USD","NGEN","LU0266013472.USD","LU1291159041.SGD","LU1892829315.USD","BK4007","LU1989771016.USD","BK4192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623315199","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2623315199","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623315199?lang=en_us&edition=fundamental","pubTime":"2026-03-30 18:00","pubTimestamp":1774864800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.26)  4:05 PM. ·Dave & Buster                                   4Q       .39   4:05 PM. ·NIKE Class B                                     3Q       .29   4:15 PM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MAZE","KEEL","MKC","NGEN","BITF","RH","MSM","PRPL","AYI","MKC.V","BNZI","LNN","PVLA","CALM","NNOX","BTBT","CRDL","AURA","CAG","INV","JILL","AIRJ","NKE","PRGS","BCAX","PVH","AIRO","AEHR","BHST","RNXT","NEOG","PHR","BIRD","ANGO","NMRA","NCNO","PENG","APOG","SGMO","INMB","SGML","PLAY","BYND","DMAC","BEEM","IMNN","FDS","FC","PROP","LW","NKLR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847966","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847966?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:00","pubTimestamp":1774605600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·SBC Med Grp Hld                                  4Q       .12       BMO. ·INmune Bio Inc                                  4Q      (.26)  4:05 PM. ·Banzai Intl Cl A                                4Q      (.59)      AMC. ·FactSet Res Sys                                  2Q      4.38   6:00 AM. ·McCormick & Co                                 1Q       .60   6:30 AM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APOG","AYI","BIRD","BYND","RNXT","HUMA","LW","PRGS","NCNO","FC","KEEL","BITF","PHR","PLAY","MSLE","DEFT","MKC","AIRJ","BEEM","BHST","KOPN","AURA","CRDL","CAG","IMNN","FDS","NKE","LNN","MSM","AIRO","KYTX","AEHR","PENG","INV","CALM","MKC.V","ANGO","ATOS","CCL","INMB","NKLR","AUTL","DMAC","BTBT","JILL","NGEN","LGN","NEOG","BNZI","BCAX","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619155776","title":"NervGen Pharma to Delist From TSX Venture Exchange","url":"https://stock-news.laohu8.com/highlight/detail?id=2619155776","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619155776?lang=en_us&edition=fundamental","pubTime":"2026-03-13 05:59","pubTimestamp":1773352748,"startTime":"0","endTime":"0","summary":"NervGen Pharma  said late Thursday it elected to voluntarily delist its common shares from the TSX Venture Exchange, effective at the close of markets Monday.The move is intended to eliminate duplicative exchange fees, reduce legal, accounting and regulatory complexity, and allow greater focus on clinical execution and long-term shareholder value.NervGen said all shareholders, including those in Canada, will continue to have full trading access to their common shares on Nasdaq.In connection with the voluntary delisting, the company said it has terminated its at-the-market equity program launched on Dec. 19, 2025.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NGEN","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616530176","title":"NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616530176","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616530176?lang=en_us&edition=fundamental","pubTime":"2026-03-04 20:30","pubTimestamp":1772627400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, March  04, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing f","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249258/0/en/NervGen-Pharma-Appoints-Shamim-Ruff-as-Chief-Regulatory-Affairs-Officer-and-Christine-McSherry-as-SVP-Patient-Advocacy-and-Clinical-Affairs.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4548","SCI","BK4192","EMA","LU1291159041.SGD","LU0077335932.USD","BK4081","LU1989771016.USD","BK4007","LU0266013472.USD","LU1892829315.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2612446940","title":"NervGen Pharma to Participate at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2612446940","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612446940?lang=en_us&edition=fundamental","pubTime":"2026-02-18 20:30","pubTimestamp":1771417800,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  18, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/18/3240099/0/en/NervGen-Pharma-to-Participate-at-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1291159041.SGD","NGEN","BK4007","EMA","SCI","LU0077335932.USD","BK4192","LU0266013472.USD","LU1892829315.USD","LU1989771016.USD","BK4081","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611903908","title":"NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams","url":"https://stock-news.laohu8.com/highlight/detail?id=2611903908","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611903908?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:15","pubTimestamp":1770930900,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  12, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/12/3237692/0/en/NervGen-Pharma-Announces-Retirement-of-Chief-Financial-Officer-Bill-Adams.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0077335932.USD","LU1989771016.USD","EMA","BK4192","BK4081","BK4548","SCI","LU1291159041.SGD","NGEN","LU1892829315.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610932627","title":"NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium","url":"https://stock-news.laohu8.com/highlight/detail?id=2610932627","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610932627?lang=en_us&edition=fundamental","pubTime":"2026-02-11 20:00","pubTimestamp":1770811200,"startTime":"0","endTime":"0","summary":"Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independenc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/11/3236120/0/en/NervGen-Pharma-to-Present-at-Unite2Fight-Paralysis-20th-Annual-Science-and-Advocacy-Symposium.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NGEN","BK4081","BK4548","LU0077335932.USD","LU1291159041.SGD","BK4007","LU1989771016.USD","LU0266013472.USD","SCI","BK4192","LU1892829315.USD","EMA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610377526","title":"NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2610377526","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610377526?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:00","pubTimestamp":1770638400,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Feb.  09, 2026  (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company\") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing fi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/09/3234390/0/en/NervGen-Pharma-Appoints-Adam-Rogers-as-Chief-Executive-Officer-to-Continue-Leading-the-Company-s-Growth-and-Execution-of-Its-Mission-in-Spinal-Cord-Injury.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","EMA","LU1892829315.USD","BK4548","LU0077335932.USD","NGEN","SCI","BK4192","BK4007","LU0266013472.USD","LU1291159041.SGD","CEO","BK4081"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":18,"code":"91000000","status":"200"}]}}